Close Menu

NEW YORK (GenomeWeb News) - Clinical Data said today it has paid out 135,146 of its shares to Merck KGaA as a milestone payment after successfully completing a Phase III study of the German firm’s Vilazodone drug.

Clinical Data’s shares closed most recently at $24.22.

Clinical Data acquired the rights to antidepressant Vilazodone in 2004 and is developing the drug along with a genetic test that will help doctors match patients with a treatment that is most likely to work in the first instance.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A group of statisticians wants to eliminate researchers' reliance on 'statistical significance,' according to NPR.

Newsweek discusses the privacy issues raised by digital medicine.

In Nature this week: genetic analysis of Anatolian farmers, cotton genome analysis, and more.

Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.